(Photo: iStock).

Supply of Dulaglutide, sold under the brand name Trulicity, 3mg/0.5ml and 4.5mg/0.5ml solution for injection pre-filled pens will remain out of stock until mid-April 2022.

This follows issuance of a Medicine Supply Notification (MSN) for the medication, used for the treatment of type 2 diabetes, by the Department of Health and Social Care (DHSC).

DHSC stated that Dulaglutide 0.75mg/0.5ml and 1.5mg/0.5ml solution are available and can support an uplift in demand.

In a separate notification, the department has notified MSN for Mesalazine (Asacol) 400mg and 800mg MR gastro-resistant tablets, which would remain out of stock until mid-March 2022.

It stated that Octasa MR 400mg and 800mg tablets are available and can support a full uplift in demand during this period.

In cases where Octasa MR tablets are not considered appropriate, other mesalazine tablets remain available to meet patients’ needs.

If you want to share your stories and/or experiences with us, please send an email to [email protected]